Patent details

Basic Information

Publication number:

EP3416627

PCT Application Number:

EP2018060547

Type:

European Patent Granted for LU

Legal Status:

Revoked

Application number:

EP187184767

PCT Publication Number:

WO2018197538

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ORAL DOSAGE FORM COMPRISING RIFAXIMIN IN FORM BETA

French Title of Invention:

FORME POSOLOGIQUE ORALE COMPRENANT DE LA RIFAXIMINE SOUS FORME BÊTA

German Title of Invention:

ORALE DARREICHUNGSFORM MIT RIFAXIMIN IN DER FORM BETA

SPC Number:

Dates

Filing date:

25/04/2018

Grant date:

27/11/2019

EP Publication Date:

26/12/2018

PCT Publication Date:

01/11/2018

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

27/11/2019

EP B1 Publication Date:

27/11/2019

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

25/04/2020

Expiration date:

25/04/2038

Renunciation date:

Revocation date:

06/02/2024

Annulment date:

Owner

From:

20/11/2019

 

 

Name:

Sandoz AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

Name:

SCHWARZ, Franz Xaver

Address:

Austria (AT)

Priority

Priority Number:

17168281

Priority Date:

26/04/2017

Priority Country:

European Patent Office (EPO) (EP)

Classification

IPC classification:

A61K 9/20; A61K 31/437;

Publication

European Patent Bulletin

1

Issue number:

201948

Publication date:

27/11/2019

Description:

Grant (B1)

2

Issue number:

202424

Publication date:

12/06/2024

Description:

Revocation of the European patent

3

Issue number:

202017

Publication date:

22/04/2020

Description:

Document reprinted after correction (B8, B9)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages